# Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)

> **NCT07404345** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Hospital Civil de Guadalajara** · enrollment: 54 (estimated)

## Conditions studied

- Hemodialysis Access Failure
- Kidney Disease, End-Stage
- Hemodialysis Catheter

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Heparin sodium lock solution

## Key facts

- **NCT ID:** NCT07404345
- **Lead sponsor:** Hospital Civil de Guadalajara
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07404345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07404345, "Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07404345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*